Chaim Hurvitz - Oct 21, 2022 Form 4 Insider Report for NRX Pharmaceuticals, Inc. (NRXP)

Role
Director
Signature
/s/ Chaim Hurvitz
Stock symbol
NRXP
Transactions as of
Oct 21, 2022
Transactions value $
$514,905
Form type
4
Date filed
11/21/2022, 04:58 PM
Previous filing
Jun 10, 2021
Next filing
Sep 27, 2023
This filing has been restated, see here for the amended filing

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NRXP Common Stock Purchase $285K +288K $0.99 288K Nov 16, 2022 Direct F1
transaction NRXP Common Stock Purchase $186K +172K +59.68% $1.08 460K Nov 17, 2022 Direct F2
transaction NRXP Common Stock Purchase $44.4K +40.4K +8.79% $1.10 500K Nov 18, 2022 Direct F3
holding NRXP Common Stock 1.44M Oct 21, 2022 By Shirat HaChaim Ltd.
holding NRXP Common Stock 208K Oct 21, 2022 By CH Health-Private Venture Capital Ltd.

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NRXP Employee Stock Option Award +163K +74.47% 381K Oct 21, 2022 Common Stock 163K $0.75 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported above reflects the weighted average purchase price per share of common stock (the "Common Stock"), of NRx Pharmaceuticals, Inc. (the "Issuer"). The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
F2 The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common Stock and prices at which the transaction was effected.
F3 The price reported above reflects the weighted average purchase price per share of the Common Stock. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer or any security holder of the Issuer, upon request, full information regarding the number of shares of the Common
F4 Options issued under the NRx Pharmaceuticals, Inc. 2021 Omnibus Incentive Plan. The options vest on May 25, 2023, generally subject to the Reporting Person's continued service for the Issuer.